P1.001. Obesity and Metabolic Surgery: Association of Gastroesophageal Reflux Disease, Barrett's Esophagus, and Esophageal Adenocarcinoma With an Emphasis on Sleeve Gastrectomy
Abstract
Benign Disease: Gastro-Esophageal Reflux and Hiatal Hernia
Obesity is a global epidemic associated with various comorbidities, including gastroesophageal reflux disease (GERD), Barrett's esophagus (BE), and esophageal adenocarcinoma. Surgical treatment of obesity, particularly sleeve gastrectomy (SG), has gained widespread popularity due to its efficacy in weight loss and metabolic improvement. However, SG presents a recognized refluxogenic profile, raising concerns about the development of de novo GERD, inflammatory changes in the esophageal mucosa, and potential progression to BE and esophageal cancer.
This study consists of a narrative literature review based on articles published between 2020 and 2025, primarily retrieved from the PubMed and Medline databases. Prospective and retrospective studies, systematic reviews, and consensus statements addressing the relationship between obesity, bariatric surgery, GERD, Barrett's esophagus, and esophageal adenocarcinoma were analyzed, with a specific focus on sleeve gastrectomy
The reviewed data demonstrate that SG is associated with an increased incidence of GERD and erosive esophagitis in the postoperative period compared with the preoperative state. The incidence of Barrett's esophagus after SG varies widely among studies, ranging from 1% to 27%, with mean values around 9% to 15%, with most cases classified as de novo and non-dysplastic. Despite the increased reflux, progression to esophageal adenocarcinoma remains rare, with…
Read the paper
Related studies
- Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use
- Ivth brazilian consensus conference on helicobacter pylori infection
- A pSMAD/CDX2 complex is essential for the intestinalization of epithelial metaplasia
- S2k-Leitlinie Gastroösophageale Refluxkrankheit und eosinophile Ösophagitis der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – März 2023 – AWMF-Registernummer: 021–013
- Step-by-step management of refractory gastresophageal reflux disease
- Insights into Effects/Risks of Chronic Hypergastrinemia and Lifelong PPI Treatment in Man Based on Studies of Patients with Zollinger–Ellison Syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.